FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today announced participation details for the May 24th FDA Circulatory System Devices Advisory Panel Meeting, where worldwide data was reviewed for the GORE HELEX Septal Occluder, indicated for closure of Atrial Septal Defects (ASD). The FDA convened the meeting to discuss current knowledge about the safety and effectiveness of devices approved for transcatheter ASD closure. Satisfied with meeting outcomes, Gore valued the opportunity to participate and have the FDA and Advisory Panel review more than a decade of clinical experience with the GORE HELEX device.